Nivolumab-induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: A case report

Lichenoid granulomatous reactions (LGR) are granulomatous inflammations of the skin and oral mucosa, also sharing features of lichenoid lesions. Thus, the present study refers to lichenoid granulomatous dermatitis (LGD) and lichenoid granulomatous stomatitis (LGS). LGR is a condition that can be triggered by drugs, diseases or environmental causes. In the present case study, anti-PD1 (nivolumab) medication had a detrimental effect on the oral mucosa, which clinicaly and histologicaly proved to be LGS. Checkpoint inhibitors consitute a cornerstone in the current treatment of several types of cancer, of which cutaneous melanoma is the best example. Oral lichenoid responses following anti-PD-1 therapy have been recorded in few case reports and small case series. To the best of our knowledhe, this is the first case of LGS being reported as a side effect of immune checkpoint inhibitor treatment.

[1]  A. Alessandrini,et al.  Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies , 2021, Journal of clinical medicine.

[2]  R. Motzer,et al.  Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. , 2020, Cancer.

[3]  R. Mesquita,et al.  Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus. , 2020, Oral diseases.

[4]  S. Fitzpatrick,et al.  Lichenoid reaction with granulomatous stomatitis: a retrospective histologic study of 47 patients. , 2019, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[5]  H. Nakatani,et al.  Drug-induced oral lichenoid reaction during nivolumab therapy. , 2019, International journal of oral and maxillofacial surgery.

[6]  J. Diaz-Perez,et al.  Granulomatous and lichenoid dermatitis after IgG4 anti‐PD‐1 monoclonal antibody therapy for advanced cancer , 2018, Journal of cutaneous pathology.

[7]  Y. Amoh,et al.  Oral lichenoid reaction showing multiple ulcers associated with anti‐programmed death cell receptor‐1 treatment: A report of two cases and published work review , 2018, The Journal of dermatology.

[8]  K. Rieger,et al.  Granuloma annulare associated with immune checkpoint inhibitors , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  R. Motzer,et al.  Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  C. Lombard,et al.  Nivolumab-Induced Granulomatous Inflammation of the Pleura. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  J. Epstein,et al.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors , 2017, Supportive Care in Cancer.

[12]  H. Yokozeki,et al.  Severe Oral Ulcers Associated With Nivolumab Treatment. , 2017, JAMA dermatology.

[13]  S. Gettinger,et al.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.

[14]  J. Utikal,et al.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[15]  L. Vercellino,et al.  Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. , 2016, Chest.

[16]  R. Novoa,et al.  Immunohistochemical analysis of lichenoid reactions in patients treated with anti‐PD‐L1 and anti‐PD‐1 therapy , 2016, Journal of cutaneous pathology.

[17]  Spring Golden,et al.  New-onset oral lichen planus and granulomatous cheilitis in a 66-year-old woman , 2016, JAAD case reports.

[18]  A. Amin,et al.  Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. , 2015, Translational lung cancer research.

[19]  A. Errico.  Immunotherapy: PD-1–PD-L1 axis: efficient checkpoint blockade against cancer , 2015, Nature Reviews Clinical Oncology.

[20]  J. Saurat,et al.  Giant cell lichenoid dermatitis in a patient with baboon syndrome , 2008, Journal of cutaneous pathology.

[21]  J. Oxley,et al.  Lichenoid and granulomatous stomatitis: an entity or a non-specific inflammatory process? , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[22]  D. James.  A clinicopathological classification of granulomatous disorders , 2000, Postgraduate medical journal.

[23]  C. Magro,et al.  Lichenoid and granulomatous dermatitis , 2000, International journal of dermatology.

[24]  M. D. Marcus,et al.  Giant cell lichenoid dermatitis. , 1986, Journal of the American Academy of Dermatology.